4.055
1.21%
-0.065
前日終値:
$4.12
開ける:
$4.13
24時間の取引高:
158.08K
Relative Volume:
0.72
時価総額:
$211.88M
収益:
$21.05M
当期純損益:
$-89.22M
株価収益率:
-1.4031
EPS:
-2.89
ネットキャッシュフロー:
$-64.50M
1週間 パフォーマンス:
-15.56%
1か月 パフォーマンス:
-22.77%
6か月 パフォーマンス:
-56.14%
1年 パフォーマンス:
-2.63%
Tscan Therapeutics Inc Stock (TCRX) Company Profile
TCRX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
TCRX | 4.055 | 211.88M | 21.05M | -89.22M | -64.50M | -2.89 |
VRTX | 449.72 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 747.06 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 595.00 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.52 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-05-16 | 開始されました | BTIG Research | Buy |
2024-05-13 | 開始されました | Needham | Buy |
2023-06-22 | 開始されました | Wedbush | Outperform |
Tscan Therapeutics Inc (TCRX) 最新ニュース
LMR Partners LLP Trims Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
Tscan therapeutics sees $4,113 stock purchase by Lynx1 capital - Investing.com India
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? - MSN
Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com
TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World
FY2024 Earnings Estimate for TCRX Issued By Lifesci Capital - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Wedbush Research Analysts Boost Earnings Estimates for TCRX - MarketBeat
TScan Therapeutics Inc (TCRX) Quarterly 10-Q Report - Quartzy
Wedbush Has Positive Forecast for TCRX FY2028 Earnings - MarketBeat
TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts By Investing.com - Investing.com Nigeria
TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts - Investing.com India
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Needham & Company LLC Reaffirms “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World
TScan Therapeutics Reports Q3 2024 Financial Results - TipRanks
Tscan Therapeutics earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
New Blood Cancer Treatment Shows Continued Response - Streetwise Reports
Tscan Therapeutics Inc’s (TCRX) 7.56% Increase Justifies A Second Look - Stocks Register
TScan Therapeutics' (TCRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet? - Simply Wall St
TScan Therapeutics' SWOT analysis: innovative therapy stock faces pivotal year - Investing.com Australia
TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire
TScan's Blood Cancer Trial Shows Zero Relapses: Breakthrough Phase 1 Results | TCRX Stock News - StockTitan
Waltham cancer biotech adds to real estate footprint - The Business Journals
TScan Therapeutics (NASDAQ:TCRX) Enters Second Amendment for Lease Agreement to Expand Operations at Winter Street FacilityOn October 28, 2024, TScan Therapeutics, Inc. finalized a second amendment to its lease agreement with PPF OFF 828-83 - Defense World
TScan expands Waltham facility with additional lease - Investing.com India
TScan expands Waltham facility with additional lease By Investing.com - Investing.com UK
Head to Head Review: ProKidney (NASDAQ:PROK) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World
The Manufacturers Life Insurance Company Invests $90,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Where are the Opportunities in (TCRX) - Stock Traders Daily
BTIG Initiates Coverage of TScan Therapeutics (TCRX) with Buy Recommendation - MSN
Bank of Montreal Can Acquires Shares of 120,454 TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
Bank of Montreal Can Invests $749,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
(TCRX) On The My Stocks Page - Stock Traders Daily
TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Lifted by Marshall Wace LLP - MarketBeat
American Century Companies Inc. Increases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TCRXTScan Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
TScan Therapeutics Announces Upcoming Presentations at the - GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - StockTitan
Reviewing TScan Therapeutics (NASDAQ:TCRX) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Tscan Therapeutics Inc [TCRX] Stock bought by Insider Klencke Barbara for $26450.0 - Knox Daily
Was there any good news for Tscan Therapeutics Inc (TCRX) stock in the last session? - US Post News
Market Momentum Report: Tscan Therapeutics Inc (TCRX)’s Negative Close at 4.98 - The Dwinnex
TScan Therapeutics's SWOT analysis: biotech stock faces pivotal year - Investing.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Sees Significant Growth in Short Interest - MarketBeat
92,832 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Bought by Troluce Capital Advisors LLC - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Barbara Klencke Acquires 5,000 Shares - Defense World
TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com South Africa
Tscan Therapeutics Inc (TCRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):